Huons Turns to Operating Profit of 2.9 Billion Won in Q2, Returning to Profitability from Previous Quarter

Separate Sales at 117.6 Billion Won, Operating Profit at 7.3 Billion Won
Growth Driven by Increased Vaccine and Pharmaceutical Sales

Huons succeeded in turning a profit in consolidated operating income in the second quarter of this year. Increased sales in the domestic pharmaceutical and vaccine businesses drove the improved results.

On August 11, Huons announced consolidated second-quarter sales of 147 billion won and operating profit of 2.9 billion won. Compared to the previous quarter, sales increased by 3.6%, and operating profit turned positive. However, sales decreased by 5.8% year-over-year.

On a separate (non-consolidated) basis, sales were 117.6 billion won and operating profit was 7.3 billion won, up 6.4% and 485.7% respectively from the previous quarter. Consolidated sales declined year-over-year due to factors such as the termination of the continuous glucose monitoring business and a temporary halt in exports to the United States. On the other hand, an increase in sales from the domestic pharmaceuticals and new vaccine businesses led to higher sales compared to the previous quarter.

Operating profit, which was in the red in the first quarter due to costs related to a voluntary recall of products exported to the United States, turned positive in the second quarter. Although selling and administrative expenses decreased, higher cost of goods sold due to initial expenses for operating a new production line, as well as costs for improvements and reorganization of facilities for Good Manufacturing Practice (GMP) pharmaceutical manufacturing and quality control, resulted in lower profits compared to the same period last year.

For the second half of 2026, Huons plans to pursue further improvements in performance by expanding its vaccine distribution business and improving the utilization rate of the parenteral (injection) production line at the second plant. The company also expects to benefit from reduced selling and administrative expenses as a result of the merger with Huons Life Science.

Meanwhile, on the same day, Huons held a board meeting and resolved to pay a cash dividend of 200 won per share. The record date for the dividend is August 31, with payment scheduled for September 16. The total dividend amount is 2.3 billion won.

This content was produced with the assistance of AI translation services.